Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck

News

Home > News > Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck

Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck

Circadin Australia

This website is intended to provide qualified Healthcare Professionals (HCPs) with information and support on insomnia management. This website contains promotional information.

News

Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck

News & Views

Stay informed!

Improve your Sleep Knowledge.